ADCT vs GSK · rev $40.1M vs P/E 13, $103.31B cap
ADC Therapeutics SA (ADCT) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported ADCT revenue for 2026-06-30 was $40.1M. Net income was -$49.5M. Revenue was up 92.3% from 2026-03-31 to 2026-06-30. ADCT currently screens at market cap $141.2M.
GSK does not have a complete income-statement cache yet.
ADCT currently screens at market cap $141.2M. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the ADCT and GSK stock pages for the full models.
Not investment advice.